BioLife Solutions, Inc. (NASDAQ: BLFS), a top provider of bioproduction tools for the cell and gene therapy (CGT) market, has signed a multi-year supply agreement…
February 12, 2026
February 09, 2026
OraGenics Targets $9B Concussion Market With Clinical-Stage Intranasal Therapy ONP-002
OraGenics, Inc. (NYSE American: OGEN) outlined its 2026 clinical and operational roadmap as it advances ONP-002, an intranasal neurosteroid candidate positioned as a potential first-in-class…
January 20, 2026
GSK Finalizes $2.2 Billion Acquisition of RAPT Therapeutics, Targeting Food Allergy Market
GSK (NYSE: GSK) has announced its acquisition of RAPT Therapeutics for $2.2 billion, marking the first major strategic move under newly appointed CEO Luke Miels….
January 07, 2026
BBOT’s ON/OFF Biology: A Game-Changer in Oncology
BridgeBio Oncology Therapeutics Inc. (NASDAQ: BBOT) unveiled promising updates across its oncology pipeline, solidifying its position as a leader in innovative cancer therapies. The standout…
Immunic, Inc. (NASDAQ: IMUX) made meaningful progress in 2025 toward advancing vidofludimus calcium as a potential treatment for relapsing multiple sclerosis (RMS), highlighted by the completion of…
Aktis Oncology Inc., a clinical-stage biotechnology firm specializing in radiopharmaceutical cancer treatments, has announced plans for a U.S. initial public offering (IPO) aiming to raise…
December 22, 2025
Pluri and Remedy Cell Expand Partnership, Reach Clinical-Grade Manufacturing Milestone
Pluri (NASDAQ: PLUR) and Remedy Cell have expanded their manufacturing collaboration, achieving an important milestone as clinical-grade production of Remedy Cell’s lead therapeutic candidate has…
December 22, 2025
Atea Pharmaceuticals Completes Enrollment in North American Phase 3 Hepatitis C Trial
Atea Pharmaceuticals (NASDAQ: AVIR) has completed patient enrollment in its C-BEYOND Phase 3 clinical trial, a pivotal study evaluating an oral, fixed-dose combination of bemnifosbuvir…
December 18, 2025
BioNTech Completes CureVac Acquisition, Expanding Its mRNA Platform
BioNTech SE ( NASDAQ: BNTX) has completed its acquisition of CureVac N.V., closing its public exchange offer and moving toward full integration of the two…
December 17, 2025
VYNE Therapeutics and Yarrow Bioscience Agree to Merge, Creating Thyroid-Focused Biotech
VYNE Therapeutics Inc. (NASDAQ: VYNE) and Yarrow Bioscience, Inc. have entered into a definitive all-stock merger agreement to combine their operations and form a new…
December 09, 2025
December’s Hidden Risk: Investing in the Age of Identity Theft
During National Identity Theft Prevention and Awareness Month, consumers may guard their passwords, but the financial world is focused on the new identity asset class:…
December 03, 2025
Capricor Soars on Positive Phase 3 HOPE-3 Trial Results for their Duchenne Muscular Dystrophy (DMD) Study
Capricor Therapeutics (NASDAQ: CAPR) announced significant positive topline results from its pivotal Phase 3 HOPE-3 clinical trial. The study evaluated Deramiocel, an investigational cell therapy…